Obesity & Metabolic
Expertise & data to help you navigate a dynamic landscape

The advent of novel anti-obesity medications, led by GLP-1-based treatments, is transforming the management of obesity and related conditions…
Having tracked the obesity market for many years, Ipsos has accelerated our work in this dynamic space in line with client need. Our global portfolio includes:
Custom Research, Market Access & Advisory Services
From a firm foundation of therapy area expertise, market knowledge, and unrivalled access to all relevant stakeholders, we conduct qual and quant custom research, ethnographic studies, social intelligence, market access and strategic advisory services to answer business questions across the obesity and metabolic product lifecycles.
Multi-Client Monitors (Real-world Data + Stakeholder Perceptions)
Our expert-led multi-client monitors provide an evolving 360⁰ view of the dynamic obesity landscape, and include:
- Ipsos Global Obesity & Cardiometabolic Disease Therapy Monitor
- Ipsos Global Consumer Obesity Monitor
- Ipsos GLP-1 Market Sizing Monitor
- Ipsos MASH Therapy Monitor
Learn more: Ipsos Monitors the Obesity Treatment Revolution
Recent thought leadership
PoV: Predicting Opportunity in Emerging Therapies
PoV: The Unseen Struggle of Type 1 Diabetes Patients
Paper: Revolutionizing Diabetes Care: Rise of the Digital Ecosystem
PoV: GLP-1s beyond weight loss
PoV: Brand Success in the GLP-1 Era: Harnessing Context, Empathy & Expectations
Media Comment (PharmExec): Building Awareness of Anti-Obesity Drugs
Webinar Recording: The Changing Landscape of Obesity in America
Research insights: The Consumer Response to GLP-1s
Research insights: The HCP Response to GLP-1s
Report (for J&J Medical) Obesity: An Empathy Blind Spot
Talk to us about your obesity business questions.